Free Trial
→ Elon’s FINAL Warning? [US Dollar Collapse] (From International Living) (Ad)tc pixel Free SHPH Stock Alerts

Shuttle Pharmaceuticals (SHPH) Financials

Shuttle Pharmaceuticals logo
$5.58 +0.88 (+18.58%)
As of 12:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Shuttle Pharmaceuticals

Annual Income Statements for Shuttle Pharmaceuticals

This table shows Shuttle Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Costs & Expenses		 - - - - 12
Net Income / (Loss) Attributable to Common Shareholders		 -1.26 -6.75 -6.59 -9.14 -12
Consolidated Net Income / (Loss)		 -1.15 -5.00 -6.59 -9.14 -12
Net Income / (Loss) Continuing Operations		 -1.15 -5.00 -6.59 -9.14 -12
Total Pre-Tax Income 		-1.15 -5.00 -6.59 -9.14 -12
Total Operating Income		 -1.74 -2.34 -5.89 -7.70 -12
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 1.74 2.34 5.89 7.70 12
Selling, General & Admin Expense		 0.04 0.47 1.05 1.39 5.67
Research & Development Expense		 1.02 1.05 3.52 3.62 4.05
Other Special Charges / (Income)		 0.68 0.82 1.33 2.68 2.19
Total Other Income / (Expense), net		 0.59 -2.65 -0.70 -1.45 0.20
Interest Expense		 0.05 0.48 2.49 1.21 -0.27
Interest & Investment Income		 - 0.00 0.08 0.07 0.00
Other Income / (Expense), net		 0.64 -2.17 1.71 -0.31 -0.07
Basic Earnings per Share		 ($0.12) ($5.04) ($3.53) ($79.65) ($7.16)
Weighted Average Basic Shares Outstanding		 9.30M 1.34M 1.87M 114.81K 1.64M
Diluted Earnings per Share		 - ($5.04) ($3.53) ($82.60) ($7.16)
Weighted Average Diluted Shares Outstanding		 - 1.34M 1.87M 115.49K 1.64M
Weighted Average Basic & Diluted Shares Outstanding		 - 13.65M 16.79M 4.08M 5.59M

Quarterly Income Statements for Shuttle Pharmaceuticals

This table shows Shuttle Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Costs & Expenses		 - - - - - - - - - 2.22 3.95
Net Income / (Loss) Attributable to Common Shareholders		 -1.64 -1.73 -2.03 -3.78 -1.60 -3.05 -3.71 -2.35 -2.61 -2.15 -3.15
Consolidated Net Income / (Loss)		 -1.64 -1.73 -2.03 -3.78 -1.60 -3.05 -3.71 -2.35 -2.61 -2.15 -3.15
Net Income / (Loss) Continuing Operations		 -1.64 -1.73 -2.03 -3.78 -1.60 -3.05 -3.71 -2.35 -2.61 -2.15 -3.15
Total Pre-Tax Income 		-1.64 -1.73 -2.03 -3.78 -1.60 -3.05 -3.71 -2.35 -2.61 -2.15 -3.15
Total Operating Income		 -1.28 -1.38 -1.48 -3.05 -1.78 -2.95 -3.91 -2.27 -2.79 -2.22 -3.95
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 1.28 1.38 1.48 3.05 1.78 2.95 3.91 2.27 2.79 2.22 3.95
Selling, General & Admin Expense		 0.32 0.32 0.31 0.33 0.43 0.60 2.35 0.89 1.84 1.16 1.98
Research & Development Expense		 0.71 0.59 0.65 1.40 0.99 1.57 1.03 0.94 0.51 0.27 0.06
Other Special Charges / (Income)		 0.26 0.47 0.53 1.32 0.36 0.78 0.54 0.44 0.43 0.79 1.91
Total Other Income / (Expense), net		 -0.36 -0.35 -0.55 -0.73 0.18 -0.10 0.20 -0.08 0.17 0.06 0.80
Interest Expense		 0.53 0.50 0.43 0.27 0.01 0.01 0.02 0.02 -0.32 0.01 -0.76
Interest & Investment Income		 0.03 0.03 0.05 0.06 -0.07 0.00 0.00 0.00 0.00 0.00 0.00
Other Income / (Expense), net		 0.15 0.13 -0.17 -0.52 0.26 -0.09 0.23 -0.06 -0.15 0.08 0.05
Basic Earnings per Share		 ($0.88) ($0.83) ($24.12) ($39.83) ($13.92) ($7.60) ($32.91) ($1.05) ($1.60) ($0.43) ($3.10)
Weighted Average Basic Shares Outstanding		 1.87M 2.08M 84.20K 95.00K 114.81K 401.96K 112.61K 2.23M 1.64M 5.03M 1.02M
Diluted Earnings per Share		 ($0.88) ($0.83) ($24.12) ($39.83) ($13.92) ($7.60) ($32.91) ($1.05) ($1.60) ($0.43) ($3.10)
Weighted Average Diluted Shares Outstanding		 1.87M 2.08M 84.20K 95.00K 115.49K 401.96K 112.61K 2.23M 1.64M 5.03M 1.02M
Weighted Average Basic & Diluted Shares Outstanding		 16.79M 16.79M 2.23M 3.66M 4.08M 10.98M 1.07M 1.60M 5.59M 5.85M 4.76M

Annual Cash Flow Statements for Shuttle Pharmaceuticals

This table details how cash moves in and out of Shuttle Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.39 7.91 -5.84 -0.66 -1.59
Net Cash From Operating Activities		 -0.30 -2.67 -5.58 -7.33 -9.48
Net Cash From Continuing Operating Activities		 -0.30 -2.67 -5.58 -7.33 -9.48
Net Income / (Loss) Continuing Operations		 -1.15 -5.00 -6.59 -9.14 -12
Consolidated Net Income / (Loss)		 -1.15 -5.00 -6.59 -9.14 -12
Depreciation Expense		 0.01 0.01 0.01 0.01 0.29
Amortization Expense		 0.06 0.38 2.12 1.08 0.06
Non-Cash Adjustments To Reconcile Net Income		 0.21 2.27 -1.44 0.60 1.35
Changes in Operating Assets and Liabilities, net		 0.58 -0.32 0.32 0.14 0.54
Net Cash From Investing Activities		 0.00 0.00 -2.83 2.92 -3.06
Net Cash From Continuing Investing Activities		 0.00 0.00 -2.83 2.92 -3.06
Purchase of Property, Plant & Equipment		 - 0.00 -0.02 0.00 -3.04
Acquisitions		 - - - 0.00 -0.01
Purchase of Investments		 - 0.00 -3.00 -0.04 0.00
Sale and/or Maturity of Investments		 - 0.00 0.19 2.96 0.00
Net Cash From Financing Activities		 0.69 11 2.57 3.76 11
Net Cash From Continuing Financing Activities		 0.69 11 2.57 3.76 11
Repayment of Debt		 0.00 -0.07 -0.69 -1.01 -0.26
Repurchase of Common Equity		 - - - -0.24 -0.56
Issuance of Debt		 0.69 0.60 3.94 1.04 0.00
Issuance of Common Equity		 0.00 - 0.00 3.99 12
Other Financing Activities, net		 - 10 -0.68 -0.03 0.02
Cash Interest Paid		 0.00 0.04 0.16 0.09 0.13
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Shuttle Pharmaceuticals

This table details how cash moves in and out of Shuttle Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -1.31 -1.18 -0.70 -0.54 1.76 2.59 0.31 -2.72 -1.76 0.76 -1.00
Net Cash From Operating Activities		 -1.06 -1.24 -1.40 -2.00 -2.69 -2.53 -3.36 -2.63 -0.97 -2.42 -0.57
Net Cash From Continuing Operating Activities		 -1.06 -1.24 -1.40 -2.00 -2.69 -2.53 -3.36 -2.63 -0.97 -2.42 -0.57
Net Income / (Loss) Continuing Operations		 -1.64 -1.73 -2.03 -3.78 -1.60 -3.05 -3.71 -2.35 -2.61 -2.15 -3.15
Consolidated Net Income / (Loss)		 -1.64 -1.73 -2.03 -3.78 -1.60 -3.05 -3.71 -2.35 -2.61 -2.15 -3.15
Depreciation Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.00 0.00 0.29 0.63 0.63
Non-Cash Adjustments To Reconcile Net Income		 -0.07 0.00 0.20 0.55 -0.15 0.60 -0.21 0.17 0.79 -0.04 0.05
Changes in Operating Assets and Liabilities, net		 0.17 0.04 0.04 0.99 -0.94 -0.08 0.54 -0.47 0.55 -0.87 1.90
Net Cash From Investing Activities		 0.09 0.10 1.16 1.66 - 0.00 - - -3.06 -0.04 -5.43
Net Cash From Continuing Investing Activities		 0.09 0.10 1.16 1.66 - 0.00 - - -3.06 -0.04 -5.43
Acquisitions		 - - - - - 0.00 - - - -0.04 -5.43
Net Cash From Financing Activities		 -0.33 -0.04 -0.46 -0.20 4.45 5.12 3.66 -0.10 2.27 3.21 5.00
Net Cash From Continuing Financing Activities		 -0.33 -0.04 -0.46 -0.20 4.45 5.12 3.66 -0.10 2.27 3.21 5.00
Issuance of Common Equity		 - 0.00 - - 3.99 0.00 9.51 - 2.26 3.23 0.00

Annual Balance Sheets for Shuttle Pharmaceuticals

This table presents Shuttle Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.65 8.65 5.95 2.51 10
Total Current Assets		 0.51 8.58 5.59 2.21 0.50
Cash & Equivalents		 - 8.42 2.58 1.92 0.33
Prepaid Expenses		 - 0.16 0.11 0.29 0.17
Plant, Property, & Equipment, net		 0.02 0.01 0.02 0.02 0.02
Total Noncurrent Assets		 0.12 0.06 0.33 0.28 9.96
Long-Term Investments		 - - - - 0.00
Intangible Assets		 - - - 0.00 9.84
Other Noncurrent Operating Assets		 0.12 0.06 0.33 0.28 0.11
Total Liabilities & Shareholders' Equity		 0.65 8.65 5.95 2.51 10
Total Liabilities		 2.28 0.98 1.90 1.80 8.22
Total Current Liabilities		 2.22 0.98 1.04 1.53 7.97
Short-Term Debt		 0.85 0.69 0.60 0.19 2.00
Accounts Payable		 0.83 0.13 0.28 0.60 1.45
Other Current Liabilities		 0.16 0.06 0.05 0.75 4.51
Total Noncurrent Liabilities		 0.06 0.00 0.85 0.26 0.25
Other Noncurrent Operating Liabilities		 0.06 0.00 0.72 0.26 0.25
Commitments & Contingencies		 - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.63 7.68 4.06 0.71 2.25
Total Preferred & Common Equity		 -1.63 7.68 4.06 0.71 2.25
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.63 7.68 4.06 0.71 2.25
Common Stock		 4.15 27 29 35 49
Retained Earnings		 -5.80 -19 -25 -35 -46

Quarterly Balance Sheets for Shuttle Pharmaceuticals

This table presents Shuttle Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 4.75 2.81 0.67 5.31 5.50 3.54 12 23
Total Current Assets		 4.41 2.49 0.36 4.96 5.19 3.27 2.46 0.40
Cash & Equivalents		 1.40 0.70 0.16 4.51 4.82 2.09 1.09 0.09
Prepaid Expenses		 0.13 0.14 0.10 0.45 0.37 1.17 1.37 0.31
Plant, Property, & Equipment, net		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Total Noncurrent Assets		 0.32 0.31 0.29 0.33 0.29 0.26 9.33 22
Intangible Assets		 - - - - - - 9.24 8.65
Other Noncurrent Operating Assets		 0.32 0.31 0.29 0.33 0.29 0.26 0.09 14
Total Liabilities & Shareholders' Equity		 4.75 2.81 0.67 5.31 5.50 3.54 12 23
Total Liabilities		 1.99 2.01 1.99 2.02 1.90 2.15 8.46 3.63
Total Current Liabilities		 1.49 1.38 1.66 1.78 1.69 1.96 8.31 3.48
Short-Term Debt		 0.94 0.83 0.25 0.13 0.07 0.00 4.44 0.25
Accounts Payable		 0.35 0.36 1.35 0.90 1.17 1.47 1.79 2.79
Other Current Liabilities		 0.06 0.06 0.06 0.76 0.45 0.49 2.08 0.44
Total Noncurrent Liabilities		 0.50 0.63 0.33 0.24 0.21 0.18 0.16 0.15
Other Noncurrent Operating Liabilities		 0.50 0.63 0.33 0.24 0.21 0.18 0.16 0.15
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.76 0.80 -1.32 3.29 3.61 1.39 3.35 19
Total Preferred & Common Equity		 2.76 0.80 -1.32 3.29 3.61 1.39 3.35 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2.76 0.80 -1.32 3.29 3.61 1.39 3.35 19
Common Stock		 30 30 32 41 45 45 52 71
Retained Earnings		 -27 -29 -33 -38 -41 -44 -48 -52
Other Equity Adjustments		 - - - - - - - 0.00

Annual Metrics And Ratios for Shuttle Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Shuttle Pharmaceuticals' official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 13,586,393.00 15,999,125.00 3,664,919.00 1,603,285.00
DEI Adjusted Shares Outstanding		 0.00 67,932.00 79,996.00 14,660.00 160,328.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -99.32 -82.41 -623.79 -73.11
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -298.41% 50.24% -236.55% -68.22%
EBIT Growth		 0.00% -309.99% 7.30% -91.22% -49.81%
NOPAT Growth		 0.00% -34.47% -151.40% -30.61% -54.84%
Net Income Growth		 0.00% -333.64% -31.96% -38.71% -28.18%
EPS Growth		 0.00% 0.00% -31.96% -38.71% 91.33%
Operating Cash Flow Growth		 0.00% -787.81% -109.31% -31.29% -29.40%
Free Cash Flow Firm Growth		 0.00% 0.00% -33.00% -40.43% -169.14%
Invested Capital Growth		 0.00% 104.63% -1,379.12% -79.92% 484.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 56.88% -14.10% -10.59%
EBIT Q/Q Growth		 0.00% 0.00% 29.30% -5.07% -13.39%
NOPAT Q/Q Growth		 0.00% 0.00% -14.64% -6.86% -9.27%
Net Income Q/Q Growth		 0.00% 0.00% 14.05% 0.46% -9.49%
EPS Q/Q Growth		 0.00% 0.00% 14.05% 0.46% -49.48%
Operating Cash Flow Q/Q Growth		 0.00% -23.12% -8.27% -28.57% 15.33%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -3.30% -62.89%
Invested Capital Q/Q Growth		 0.00% 0.00% 40.75% 16.47% 659.68%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.03%
Interest Burden Percent		 104.61% 110.65% 157.50% 114.25% 97.72%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 70.76% -165.17% -112.37% -383.84% -791.04%
Cash Return on Invested Capital (CROIC)		 0.00% -5,967.70% 0.00% 0.00% -338.77%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 70.76% -165.17% -112.37% -383.84% -791.04%
Return on Equity Simple (ROE_SIMPLE)		 70.76% -65.07% -162.55% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.22 -1.64 -4.12 -5.39 -8.34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.13% -96.38% -40.28% -118.34% -10,886.37%
Return On Investment Capital (ROIC_SIMPLE)		 - - -86.17% -598.98% -196.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.10 -4.52 -4.19 -8.00 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.04 -4.13 -2.06 -6.92 -12
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 3.47 1.79 4.44 1.28
Price to Tangible Book Value (P/TBV)		 0.00 3.47 1.79 4.44 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 426.83 0.00 0.00 1.16
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 -0.52 0.09 0.18 0.27 0.89
Long-Term Debt to Equity		 0.00 0.00 0.03 0.00 0.00
Financial Leverage		 -0.41 -1.15 -1.04 -1.33 -0.02
Leverage Ratio		 -0.40 1.54 1.24 1.78 4.38
Compound Leverage Factor		 -0.42 1.70 1.96 2.03 4.28
Debt to Total Capital		 -109.10% 8.20% 15.27% 21.15% 47.01%
Short-Term Debt to Total Capital		 -109.10% 8.20% 12.45% 21.15% 47.01%
Long-Term Debt to Total Capital		 0.00% 0.00% 2.82% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 209.10% 91.80% 84.73% 78.85% 52.99%
Debt to EBITDA		 -0.82 -0.17 -0.36 -0.03 -0.17
Net Debt to EBITDA		 -0.82 1.87 2.30 0.25 -0.14
Long-Term Debt to EBITDA		 0.00 0.00 -0.07 0.00 0.00
Debt to NOPAT		 -0.70 -0.42 -0.18 -0.04 -0.24
Net Debt to NOPAT		 -0.70 4.71 1.15 0.32 -0.20
Long-Term Debt to NOPAT		 0.00 0.00 -0.03 0.00 0.00
Altman Z-Score		 -18.55 12.66 -5.08 -28.48 -10.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.23 8.79 5.37 1.44 0.06
Quick Ratio		 0.00 8.63 5.26 1.25 0.04
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2.64 -3.51 -4.93 -13
Operating Cash Flow to CapEx		 0.00% 0.00% -29,303.51% 0.00% -311.41%
Free Cash Flow to Firm to Interest Expense		 0.00 -5.50 -1.41 -4.09 0.00
Operating Cash Flow to Interest Expense		 -5.91 -5.55 -2.24 -6.07 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -5.91 -5.55 -2.25 -6.07 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -0.96 0.04 -0.57 -1.02 3.92
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.00 -0.61 -0.45 4.94
Enterprise Value (EV)		 11 19 2.55 1.42 4.55
Market Capitalization		 9.97 27 7.28 3.15 2.89
Book Value per Share		 ($0.18) $0.57 $0.25 $0.19 $1.41
Tangible Book Value per Share		 ($0.18) $0.57 $0.25 $0.19 ($4.73)
Total Capital		 -0.78 8.36 4.79 0.90 4.25
Total Debt		 0.85 0.69 0.73 0.19 2.00
Total Long-Term Debt		 0.00 0.00 0.14 0.00 0.00
Net Debt		 0.85 -7.73 -4.73 -1.73 1.67
Capital Expenditures (CapEx)		 0.00 0.00 0.02 0.00 3.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.86 -0.13 -0.32 -1.05 -5.80
Debt-free Net Working Capital (DFNWC)		 -0.86 8.29 5.15 0.87 -5.46
Net Working Capital (NWC)		 -1.71 7.60 4.55 0.68 -7.46
Net Nonoperating Expense (NNE)		 -0.07 3.36 2.47 3.76 3.38
Net Nonoperating Obligations (NNO)		 0.67 -7.63 -4.62 -1.73 1.67
Total Depreciation and Amortization (D&A)		 0.06 0.38 2.13 1.08 0.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.32) $0.00 ($797.50) ($71.60)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.29M 0.00 11.48K 163.79K
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($825.00) ($71.60)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.71M 0.00 11.55K 163.79K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.71M 0.00 16.31K 559.13K
Normalized Net Operating Profit after Tax (NOPAT)		 -0.74 -1.06 -3.19 -3.51 -6.81
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -21.69 -9.39 -1.68 -6.63 0.00
NOPAT to Interest Expense		 -24.02 -3.41 -1.66 -4.46 0.00
EBIT Less CapEx to Interest Expense		 -21.69 -9.39 -1.69 -6.63 0.00
NOPAT Less CapEx to Interest Expense		 -24.02 -3.41 -1.66 -4.46 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -2.58% -4.76%

Quarterly Metrics And Ratios for Shuttle Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Shuttle Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 15,999,125.00 16,794,893.00 16,794,893.00 6,680,853.00 3,664,919.00 4,076,567.00 10,984,291.00 1,070,773.00 1,603,285.00 5,591,290.00 5,851,290.00
DEI Adjusted Shares Outstanding		 79,996.00 83,974.00 83,974.00 267,234.00 14,660.00 16,306.00 43,937.00 1,070,773.00 160,328.00 559,129.00 585,129.00
DEI Earnings Per Adjusted Shares Outstanding		 -20.51 -20.61 -24.19 -14.16 -109.04 -187.23 -84.36 -2.19 -16.31 -3.85 -5.38
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 80.34% -549.46% -37.28% -411.18% -128.78% -273.78% -189.08% 30.48% -73.42% 50.71% 10.79%
EBIT Growth		 60.47% -224.30% -12.28% -200.01% -34.06% -141.55% -122.73% 34.77% -93.14% 29.61% -5.86%
NOPAT Growth		 -141.89% 10.35% -1.16% -90.82% -38.53% -113.11% -163.75% 25.71% -56.90% 24.89% -1.00%
Net Income Growth		 39.65% -77.52% 7.01% -111.08% 2.56% -76.37% -82.48% 37.97% -63.59% 29.50% 15.13%
EPS Growth		 39.65% -77.52% 7.01% -111.08% 2.56% -76.37% -82.48% 97.36% 88.51% 94.34% 90.58%
Operating Cash Flow Growth		 -67.05% 7.39% 14.99% -30.21% -153.27% -103.94% -139.76% -31.42% 63.83% 4.34% 83.08%
Free Cash Flow Firm Growth		 0.00% -525.43% -1,731.82% -867.16% -175.37% 41.39% -54.31% -12.51% -770.78% -613.20% -971.03%
Invested Capital Growth		 -1,379.12% 78.76% 38.89% -27.62% -79.92% -221.52% -97.62% 42.58% 484.76% 709.82% 1,787.43%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -2.14% -22.27% -56.10% -162.22% 54.29% -99.76% -20.73% 36.93% -14.02% 43.23% -118.53%
EBIT Q/Q Growth		 4.70% -11.02% -31.40% -115.81% 57.42% -100.02% -21.17% 36.80% -26.09% 27.10% -82.23%
NOPAT Q/Q Growth		 19.78% -7.95% -7.06% -105.82% 41.76% -66.07% -32.50% 42.03% -23.00% 20.49% -78.16%
Net Income Q/Q Growth		 8.49% -5.52% -17.34% -86.30% 57.76% -91.00% -21.40% 36.67% -11.40% 17.68% -46.14%
EPS Q/Q Growth		 8.49% -5.52% -17.34% -86.30% 57.76% -91.00% -21.40% 68.09% -52.38% 73.13% -620.93%
Operating Cash Flow Q/Q Growth		 30.80% -16.66% -12.93% -42.83% -34.60% 6.07% -32.77% 21.71% 62.96% -148.44% 76.52%
Free Cash Flow Firm Q/Q Growth		 -48.47% -677.60% 37.04% -33.06% 57.73% -65.51% -65.76% 2.98% -227.17% -35.56% -148.92%
Invested Capital Q/Q Growth		 40.75% 39.73% -69.94% -110.32% 16.47% -7.70% -4.45% 38.89% 659.68% 70.70% 189.02%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.13% 100.00% 100.00%
Interest Burden Percent		 144.66% 137.49% 122.78% 105.99% 105.14% 100.39% 100.59% 100.79% 88.93% 100.56% 80.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -112.37% -152.02% -186.00% -427.85% -383.84% -346.19% -551.04% -27,176.19% -791.04% -326.36% -90.05%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -338.77% -233.37% -146.54%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -112.37% -152.02% -186.00% -427.85% -383.84% -346.19% -551.04% -27,176.19% -791.04% -326.36% -90.05%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -266.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.90 -0.97 -1.04 -2.14 -1.24 -2.07 -2.74 -1.59 -1.95 -1.55 -2.76
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.12% -13.11% -21.44% -50.94% -11.16% -26.37% -31.60% -76.08% -2,135.89% -115.89% -16.59%
Return On Investment Capital (ROIC_SIMPLE)		 -18.76% -26.18% -63.76% 200.50% -138.31% -60.51% -74.57% -113.82% -45.88% -19.94% -14.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.13 -1.26 -1.65 -3.57 -1.52 -3.04 -3.68 -2.33 -2.94 -2.14 -3.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.66 -0.81 -1.27 -3.32 -1.52 -3.03 -3.66 -2.31 -2.63 -1.50 -3.27
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.79 2.47 8.38 0.00 4.44 0.48 0.46 2.73 1.28 1.13 0.10
Price to Tangible Book Value (P/TBV)		 1.79 2.47 8.38 0.00 4.44 0.48 0.46 2.73 0.00 0.00 0.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.16 1.07 0.11
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.18 0.34 1.03 -0.19 0.27 0.04 0.02 0.00 0.89 1.33 0.01
Long-Term Debt to Equity		 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.20 -1.20 -1.51 -1.33 -1.24 -1.39 -25.38 -0.02 -0.16 -0.20
Leverage Ratio		 1.24 1.57 1.51 1.87 1.78 1.66 1.89 53.52 4.38 2.58 1.24
Compound Leverage Factor		 1.80 2.16 1.85 1.99 1.87 1.67 1.90 53.94 3.90 2.60 1.00
Debt to Total Capital		 15.27% 25.42% 50.76% -23.47% 21.15% 3.77% 1.78% 0.00% 47.01% 57.00% 1.29%
Short-Term Debt to Total Capital		 12.45% 25.42% 50.76% -23.47% 21.15% 3.77% 1.78% 0.00% 47.01% 57.00% 1.29%
Long-Term Debt to Total Capital		 2.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.73% 74.58% 49.24% 123.47% 78.85% 96.23% 98.22% 100.00% 52.99% 43.00% 98.71%
Debt to EBITDA		 -0.36 -0.31 -0.24 -0.04 -0.03 -0.01 -0.01 0.00 -0.17 -0.44 -0.03
Net Debt to EBITDA		 2.30 1.07 0.45 -0.02 0.25 0.48 0.41 0.00 -0.14 -0.33 -0.02
Long-Term Debt to EBITDA		 -0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.18 -0.23 -0.21 -0.05 -0.04 -0.02 -0.01 0.00 -0.24 -0.57 -0.03
Net Debt to NOPAT		 1.15 0.81 0.38 -0.02 0.32 0.68 0.58 0.00 -0.20 -0.43 -0.02
Long-Term Debt to NOPAT		 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.39 -6.08 -14.00 -87.46 -19.94 -10.62 -11.44 -17.93 -7.76 -6.67 -3.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.37 2.96 1.80 0.22 1.44 2.78 3.07 1.66 0.06 0.30 0.11
Quick Ratio		 5.26 2.82 1.69 0.09 1.25 2.53 2.85 1.07 0.04 0.13 0.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.29 -2.23 -1.41 -1.87 -0.79 -1.31 -2.17 -2.11 -6.89 -9.34 -23
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -0.54 -4.49 -3.27 -6.87 -120.73 -109.79 -99.85 -111.42 0.00 -770.62 0.00
Operating Cash Flow to Interest Expense		 -2.00 -2.49 -3.25 -7.33 -410.40 -211.81 -154.31 -138.95 0.00 -199.42 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2.00 -2.49 -3.25 -7.33 -410.40 -211.81 -154.31 -138.95 0.00 -199.42 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.57 -0.34 -0.58 -1.22 -1.02 -1.10 -1.15 -0.70 3.92 6.69 19
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.61 1.27 0.37 -0.26 -0.45 -0.76 -0.57 0.52 4.94 7.79 20
Enterprise Value (EV)		 2.55 3.57 5.20 3.06 1.42 -2.80 -3.10 1.71 4.55 7.14 2.06
Market Capitalization		 7.28 6.82 6.71 2.96 3.15 1.59 1.65 3.80 2.89 3.80 1.90
Book Value per Share		 $0.25 $0.16 $0.05 ($0.59) $0.19 $0.81 $0.33 $1.30 $1.41 $2.09 $3.28
Tangible Book Value per Share		 $0.25 $0.16 $0.05 ($0.59) $0.19 $0.81 $0.33 $1.30 ($4.73) ($3.68) $1.80
Total Capital		 4.79 3.70 1.63 -1.07 0.90 3.41 3.67 1.39 4.25 7.78 19
Total Debt		 0.73 0.94 0.83 0.25 0.19 0.13 0.07 0.00 2.00 4.44 0.25
Total Long-Term Debt		 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.73 -3.25 -1.51 0.09 -1.73 -4.38 -4.75 -2.09 1.67 3.35 0.16
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.32 -0.32 -0.41 -1.20 -1.05 -1.21 -1.25 -0.79 -5.80 -2.50 -2.92
Debt-free Net Working Capital (DFNWC)		 5.15 3.86 1.93 -1.05 0.87 3.31 3.56 1.30 -5.46 -1.41 -2.83
Net Working Capital (NWC)		 4.55 2.92 1.10 -1.30 0.68 3.18 3.50 1.30 -7.46 -5.84 -3.08
Net Nonoperating Expense (NNE)		 0.74 0.76 0.99 1.65 0.35 0.99 0.97 0.76 0.66 0.60 0.38
Net Nonoperating Obligations (NNO)		 -4.62 -3.10 -1.38 0.10 -1.73 -4.38 -4.75 -2.09 1.67 3.35 0.16
Total Depreciation and Amortization (D&A)		 0.47 0.45 0.39 0.25 0.00 0.01 0.02 0.02 0.30 0.65 0.63
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.04) $0.00 ($24.00) ($39.75) ($3,480.00) ($75.00) ($32.90) ($1.05) ($16.00) ($4.30) ($3.10)
Adjusted Weighted Average Basic Shares Outstanding		 233.28K 0.00 84.20K 95.37K 459.00 40.20K 112.61K 2.23M 163.79K 503.16K 1.02M
Adjusted Diluted Earnings per Share		 ($7.04) $0.00 ($24.00) ($39.75) ($3,480.00) ($75.00) ($32.90) ($1.05) ($16.00) ($4.30) ($3.10)
Adjusted Weighted Average Diluted Shares Outstanding		 233.28K 0.00 84.20K 95.37K 462.00 40.20K 112.61K 2.23M 163.79K 503.16K 1.02M
Adjusted Basic & Diluted Earnings per Share		 ($7.04) $0.00 $0.00 $0.00 ($3,480.00) $0.00 $0.00 $0.00 ($16.00) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.10M 0.00 89.08K 146.60K 16.31K 43.94K 107.08K 1.60M 559.13K 585.13K 4.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.72 -0.64 -0.67 -1.21 -0.99 -1.52 -2.36 -1.28 -1.65 -1.00 -1.43
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2.13 -2.53 -3.84 -13.09 -231.94 -254.91 -169.47 -123.20 0.00 -176.58 0.00
NOPAT to Interest Expense		 -1.69 -1.95 -2.41 -7.83 -189.78 -173.17 -125.89 -83.94 0.00 -128.01 0.00
EBIT Less CapEx to Interest Expense		 -2.13 -2.53 -3.84 -13.09 -231.94 -254.91 -169.47 -123.20 0.00 -176.58 0.00
NOPAT Less CapEx to Interest Expense		 -1.69 -1.95 -2.41 -7.83 -189.78 -173.17 -125.89 -83.94 0.00 -128.01 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.58% -3.96% -6.28% 0.00% -4.76% -3.65% -0.46%

Financials Breakdown Chart

Key Financial Trends

Shuttle Pharmaceuticals remains a pre-revenue company. Revenue has been reported at zero in every income statement period provided, while operating expenses have remained substantial. In Q2 2026, operating expenses totaled $3.95 million, including $1.98 million of selling, general and administrative costs, $55,661 of research and development spending, and $1.91 million of other special charges. The company reported a net loss of $3.15 million, compared with a $3.71 million loss in Q2 2025 and a $2.15 million loss in Q1 2026.

Cash-flow trends show some short-term improvement in operating burn, but the company continues to rely on financing. Net cash used in operating activities declined to $568,000 in Q2 2026 from $2.42 million in Q1 2026 and $3.36 million in Q2 2025. However, Shuttle spent $5.43 million on acquisitions during Q2 and ended the quarter with a net decrease in cash of approximately $1.00 million. Financing activities provided $5.00 million during the quarter, meaning the company’s liquidity remains dependent on external capital rather than internally generated cash.

The balance sheet expanded sharply, largely because of acquisitions and the recognition of intangible and other noncurrent assets. Total assets increased from $11.81 million at March 31, 2026, to $22.81 million at June 30, 2026, while total equity rose to $19.18 million. Nevertheless, cash fell to only $90,238, compared with $1.09 million in the prior quarter and $4.82 million a year earlier. Current liabilities of $3.48 million also substantially exceeded current assets of $396,353, highlighting significant near-term liquidity risk.

  • Operating cash burn improved sequentially: cash used in operations fell by roughly 77% from $2.42 million in Q1 2026 to $568,000 in Q2 2026.
  • Net loss improved year over year: the Q2 2026 loss of $3.15 million was smaller than the $3.71 million loss reported in Q2 2025.
  • Reported equity strengthened: total equity increased to $19.18 million in Q2 2026 from $3.35 million in Q1, although the increase appears tied largely to acquisitions and financing-related activity rather than profitability.
  • Debt declined sharply on the latest balance sheet: short-term debt fell from $4.44 million at March 31, 2026, to $250,000 at June 30, 2026.
  • Acquisition activity materially changed the balance sheet: Q2 investing cash outflows of $5.43 million were attributed to acquisitions, while intangible assets reached $8.65 million and other noncurrent operating assets reached $13.75 million.
  • Share-count data is highly volatile: reported basic weighted-average shares ranged from 112,611 in Q2 2025 to 5.03 million in Q1 2026 and 1.02 million in Q2 2026, making period-to-period EPS comparisons difficult.
  • The company has not generated revenue: zero revenue has been reported across all periods provided, leaving no evidence of a commercial operating base or gross-profit generation.
  • Losses remain persistent: Shuttle reported net losses in every quarter shown, with retained earnings reaching a deficit of $51.60 million by June 30, 2026.
  • Liquidity is extremely weak: Q2 cash of $90,238 covered only a small fraction of $3.48 million in current liabilities, producing a current ratio of approximately 0.11.
  • Financing dependence and dilution remain major risks: the company has repeatedly raised capital while operating cash flow remains negative, and Q2 2026 financing provided $5.00 million despite only $574 being specifically identified as common-equity issuance in the standardized data.
10/08/26 12:01 PM ETAI Generated. May Contain Errors.

Shuttle Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Shuttle Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Shuttle Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$11.72 million in 2025, falling from -$1.15 million in 2021. The previous period was -$9.14 million in 2024. See where experts think Shuttle Pharmaceuticals is headed by visiting Shuttle Pharmaceuticals' forecast page.

Shuttle Pharmaceuticals' total operating income in 2025 was -$11.92 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.92 million

Over the last 4 years, Shuttle Pharmaceuticals' total revenue changed from $0.00 in 2021 to $0.00 in 2025, a change of 0.0%.

In the past 9 quarters, Shuttle Pharmaceuticals' cash and equivalents has ranged from $90.24 thousand in Q2 2026 to $4.82 million in Q2 2025, and is currently $90.24 thousand as of their latest financial filing in Q2 2026.

Shuttle Pharmaceuticals had total debt of $2 million at the end of 2025, a 951.1% increase from 2024, and a 135.4% increase since 2021.

Over the last 4 years, Shuttle Pharmaceuticals' book value per share changed from -0.18 in 2021 to 1.41 in 2025.


Related Companies

Financial statements for NASDAQ:SHPH last updated on 10/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
AI learned to see and hear. Now this microcap is teaching it to smell
Morgan Stanley projects the humanoid robotics market could hit $5 trillion by 2050, with over 1 billion robots...
Capital Trends | Sponsoredtc pixel
HOST Just Entered the AI Data Center Race in a BIG Way
Host Digital Inc (NYSE American: HOST) has completed its merger with Healthy Choice Wellness Corp as of Septem...
Trading Wire | Sponsoredtc pixel
Ominous New Day in America (Get Ready for it)
A market forecaster with a 55-year track record - including calls on 1970s double-digit inflation, the 1980s S...
Weiss Ratings | Sponsoredtc pixel
Elon’s FINAL Warning? [US Dollar Collapse]
On April 25, 2023, Elon Musk issued a stark warning about the future of the US dollar. A former Wall Street...
International Living | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel